Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)
 
Sponsors and Collaborators
Argos Therapeutics
 
Contact
Jill Yarbrough
919-287-6309
 
Investigators
Robert Figlin, MD, FACP
Cedars-Sinai Medical Center
 
Christopher G Wood, MD, FACP
M.D. Anderson Cancer Center
 
ClinicalTrials.gov Identifier